ERBB2 and neoplasm: For patients whose tumor HER2 IHC status was derived prior to 2014 or using a different assay, careful considerations should be made for whether HER2-low status should be re-confirmed using the PATHWAY HER2 (4B5) assay on a freshly-cut section.